Arora Health launches physician-led perimenopause study with Veristat

Arora Health has launched a physician-led observational study on perimenopause, working with Veristat to build real-world evidence for hormone health and menopause care. The IRB-approved study will track de-identified data from women treated through Arora Health’s telehealth platform.

Why it matters: - Perimenopause affects millions of women each year, but clinical evidence for individualized treatment remains limited. - Arora Health says the study is intended to strengthen the real-world evidence base for perimenopause treatment, menopause care, and women’s hormone health. - The findings could help inform future clinical decision-making without adding burdensome study procedures for participants.

What happened: - Arora Health announced a new observational women’s health study focused on perimenopause. - Veristat is partnering on the study to support clinical research design and oversight. - The study is led by Principal Investigator Nicolai Wohns, MD. - Sean Arora, MD, Arora Health co-founder and CEO, and Shannon Arora, MD, chief medical officer, provide clinical oversight. - The study will collect de-identified clinical data from women receiving care through the Arora Health telehealth platform. - The data collection focuses on hormone replacement therapy and peptide therapy.

The details: - The study is observational, not interventional, and is designed to track routine clinical care. - Participants will continue their normal care through the Arora Health telehealth platform. - The study will not add new treatments, procedures, testing, or questionnaires. - Arora Health and Veristat say the effort is meant to support robust scientific oversight, regulatory compliance, and methodological rigor. - Veristat helped develop the observational study protocol and supported the design and execution of the clinical development program. - The study has received Institutional Review Board approval. - Arora Health plans to share updates on enrollment, study milestones, and future findings as they become available. - Dr. Wohns said women’s health, especially perimenopause and menopause within longevity medicine, remains one of the most understudied areas in healthcare. - Dr. Wohns said the study aims to generate meaningful real-world evidence that may improve care for women now and in the future.

Between the lines: - The study reflects a broader push to use telehealth-generated data for clinical research without disrupting standard care. - The observational design avoids the higher complexity of a drug trial while still trying to produce evidence that can shape practice. - Arora Health is positioning physician-led research as part of its clinical and compliance model, not just its care-delivery model. - The partnership with Veristat adds regulatory and research expertise that may help make the study more credible to clinicians and future sponsors.

What's next: - Arora Health will monitor enrollment and collect real-world data over time. - The company expects to share future study milestones and results as the research progresses. - Any eventual findings could help guide future perimenopause and menopause care decisions. - The study may also expand the evidence base for hormone-related telehealth care more broadly.

The bottom line: - Arora Health is betting that physician-led observational research can fill a major evidence gap in women’s health while keeping patient care routine and compliant.